# A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

> **NCT05143957** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Phlebotomy Dependent Polycythemia Vera

## Interventions

- **DRUG:** sapablursen

## Key facts

- **NCT ID:** NCT05143957
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-30
- **Primary completion:** 2025-06-26
- **Final completion:** 2026-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143957, "A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05143957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*